Lucira Health (NASDAQ:LHDXQ – Get Rating) and Achieve Life Sciences (NASDAQ:ACHV – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.
Valuation & Earnings
This table compares Lucira Health and Achieve Life Sciences’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Lucira Health||$93.06 million||0.02||-$64.83 million||($3.58)||-0.01|
|Achieve Life Sciences||N/A||N/A||-$42.35 million||($4.06)||-2.09|
Achieve Life Sciences has lower revenue, but higher earnings than Lucira Health. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Lucira Health, indicating that it is currently the more affordable of the two stocks.
This table compares Lucira Health and Achieve Life Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Achieve Life Sciences||N/A||-385.47%||-132.04%|
Institutional & Insider Ownership
57.0% of Lucira Health shares are owned by institutional investors. Comparatively, 21.1% of Achieve Life Sciences shares are owned by institutional investors. 30.4% of Lucira Health shares are owned by insiders. Comparatively, 1.0% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a summary of recent recommendations for Lucira Health and Achieve Life Sciences, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Achieve Life Sciences||0||0||2||0||3.00|
Achieve Life Sciences has a consensus price target of $12.50, indicating a potential upside of 47.58%. Given Achieve Life Sciences’ higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than Lucira Health.
Risk and Volatility
Lucira Health has a beta of 3.36, indicating that its stock price is 236% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.
Lucira Health beats Achieve Life Sciences on 8 of the 12 factors compared between the two stocks.
About Lucira Health
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.
About Achieve Life Sciences
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Lucira Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lucira Health and related companies with MarketBeat.com’s FREE daily email newsletter.